Advanced heart failure therapies in the Eastern Mediterranean Region: current status, challenges, and future directions

Bader, Feras; Manla, Yosef; Ghalib, Hussam; Al Matrooshi, Nadya; Khaliel, Feras; Skouri, Hadi N.

doi:10.1016/j.cpcardiol.2024.102564

Current Problems in Cardiology

2024

DOI: 10.1016/j.cpcardiol.2024.102564

|View full text |Cite

Advanced heart failure therapies in the Eastern Mediterranean Region: current status, challenges, and future directions

Feras Bader,

Yosef Manla,

Hussam Ghalib

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite2

Independent0

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Middle East Region features a growing burden of heart failure with a concomitant high burden of cardio-renal-metabolic risk factors. 6 7) Limited data are available on patients with CRS and why they get hospitalized, particularly from the Middle East. In a previous analysis, we found that one-third (34.4%) of the patients visiting the HF clinic (n=968) had CRS (referring to type II or IV).…”

mentioning

confidence: 99%

Causes of Hospitalization in Patients With Cardiorenal Syndrome Across the Spectrum of Ejection Fraction

Manla,

Kholoki,

Attallah

et al. 2024

Int J Heart Fail

Self Cite

View full text Add to dashboard Cite

mentioning

confidence: 99%

Causes of Hospitalization in Patients With Cardiorenal Syndrome Across the Spectrum of Ejection Fraction

Manla,

Kholoki,

Attallah

et al. 2024

Int J Heart Fail

Self Cite

View full text Add to dashboard Cite

Trends and findings of lipoprotein(a) testing and associated cardiovascular disease profiles: a large single-center study from the Middle East-Gulf region

Manla,

AbdelWareth,

Shantouf

et al. 2024

Front. Cardiovasc. Med.

Self Cite

View full text Add to dashboard Cite

BackgroundLipoprotein(a) [Lp(a)] is a genetically determined risk factor for atherosclerotic cardiovascular disease (CVD). Limited data are available on Lp(a) testing from the Middle-East region. Therefore, we aim to evaluate the utilization and yield of Lp(a) testing over time and characterize CVD profiles of patients with abnormal Lp(a) tasting at a single-quaternary-care center in the United Arab Emirates.MethodsUnique Lp(a) tests conducted between 07/2017 and 10-2023 were included. Overtime trends in Lp(a) test utilization and abnormal Lp(a) [defined as Lp(a) > 125 nmol/L] test findings were described. CVD rates in patients with abnormal Lp(a) were compared to those with Lp(a) ≤ 125 nmol/L using appropriate methods.ResultsIn our center, 0.95% of the patients (n = 5,677) had their Lp(a) measured, with a median level of 32 [11–82] nmol/L. Lp(a) was abnormal in 15.9% of the tests. Over the years 2018–2022, there was a 109% increase in Lp(a) testing, with concomitant up-trends in findings of abnormal Lp(a) (11.8% to 16.4%, P = 0.02). Compared to patients with Lp(a) ≤ 125 nmol/I, those with abnormal Lp(a) had higher rates of any prevalent CVD (34% vs. 25.1%, P < 0.001), CAD (25.6% vs. 17.7%, P < 0.001), HF (6.5% vs. 3.8%, P < 0.001), and stroke (7.1% vs. 4.4%, P < 0.001).ConclusionAlmost one in six patients tested for Lp(a) had abnormally elevated Lp(a), and CVD was prevalent in one-third of the patients who tested abnormal for Lp(a). The study highlights the growing awareness of the relevance of Lp(a) for CVD risk stratification and prevention.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Advanced heart failure therapies in the Eastern Mediterranean Region: current status, challenges, and future directions

Cited by 2 publications

References 45 publications

Causes of Hospitalization in Patients With Cardiorenal Syndrome Across the Spectrum of Ejection Fraction

Causes of Hospitalization in Patients With Cardiorenal Syndrome Across the Spectrum of Ejection Fraction

Trends and findings of lipoprotein(a) testing and associated cardiovascular disease profiles: a large single-center study from the Middle East-Gulf region

Contact Info

Product

Resources

About